As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaProtein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligasesArsenic binding to proteinsProspects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agentsEnhanced antitumor activity of realgar mediated by milling it to nanosize.Realgar quantum dots induce apoptosis and necrosis in HepG2 cells through endoplasmic reticulum stressArsenic promotes ubiquitinylation and lysosomal degradation of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels in human airway epithelial cellsArsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxideSystematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic.Study of Arsenic Sulfide in Solid Tumor Cells Reveals Regulation of Nuclear Factors of Activated T-cells by PML and p53.Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cellsConstruction of a metabolomics profile of arsenic trioxide effect in gastric carcinoma cell line SGC7901.The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABLCaveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cellsInduction of K562 Cell Apoptosis by As4S4 via Down-Regulating miR181.The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.Metabolism of arsenic and its toxicological relevance.Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.Targeting oncoproteins for degradation by small molecules in myeloid leukemia.Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer
P2860
Q24605527-F92F5AAB-256B-4A15-BA4A-E09F745AC8B4Q26852269-FD74F414-3EFF-4053-BA2A-02CA118F2597Q28389752-F5D95CF6-EA27-4D96-8362-3C3379F98F9EQ34554617-34D266A5-ABEE-458B-8FD2-8EA35C698097Q35091183-DA07891B-E6E2-4B16-9BB9-1FCFA57A1A26Q35787483-5CA693ED-713E-46CF-8635-C0024F91C070Q36006901-57F49E2D-3A35-460A-BCAB-B9B5C3E2730EQ36253212-34324C8D-0324-4B3A-AA68-B4B3D90291DBQ36352545-8CC72FE5-2312-4493-9124-5E5888B830BBQ36371410-F505097C-1DDE-4C17-B30C-00C1D9884B5CQ36500275-0C8E7307-6D65-4C9D-B049-A4B814A72722Q36645674-65C46DC9-9315-45DC-901D-EA0C1FFFFB2AQ36954850-17360970-C132-409D-8501-5D51CE64A720Q37027483-D36A2F40-E0C8-4691-B052-40DA4BD541EBQ37409768-EBE0C656-7657-4307-90BD-23BA44D652ECQ37591850-DA09C307-B90E-4A69-B42C-369ECB711D54Q37702614-E0CC5C6C-4984-4F38-AF36-D8DD4625F949Q37709467-AE15F6DB-6A58-451B-B2D4-AF8EEAB90F42Q37919976-912E4490-02ED-4553-B8B1-73F46BA7FB97Q38020145-FDE7B3DF-FA3D-4FF6-A41A-CE3725EAB350Q38027433-7928D0BB-D5C5-4729-B466-054B2D82D0A2Q39161582-A47D7130-8CC5-4CE3-A2EC-94D5FFAEBBB2Q47337952-F4EADF18-26BA-4A67-A286-DE52BDAD4945Q47630577-919EA48F-17E3-421A-A02D-E08FFFD7BE24Q47806060-D991CD09-D8DD-475A-8909-94C4DE75BC63Q58712613-0C8B03D0-1DC1-4B27-8975-535CA455958E
P2860
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@ast
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@en
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@nl
type
label
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@ast
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@en
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@nl
prefLabel
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@ast
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@en
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@nl
P2093
P2860
P356
P1476
As4S4 targets RING-type E3 lig ...... chronic myelogenous leukemia.
@en
P2093
Jian-Hua Mao
Jian-Xiang Liu
Keqin Kathy Li
Qiu-Hua Huang
Qun-Ye Zhang
Sai-Juan Chen
Xiao-Yan Sun
P2860
P304
21683-21688
P356
10.1073/PNAS.1016311108
P407
P577
2010-11-30T00:00:00Z